Properties		Conclusion (a)
CMR	Carcinogenicity (C)	Metribuzin is not considered to be carcinogenic, mutagenic or toxic for reproduction.
	Mutagenicity (M)
	Toxic for Reproduction (R)
Endocrine disrupting properties		According to point 3.6.5 of Annex II to Regulation (EC) No 1107/2009, as amended by Commission Regulation (EU) 2018/605, it can be concluded that metribuzin meets the ED criteria for humans for the T‐modality. Metribuzin was considered not to meet the ED criteria for EAS‐modalities for humans and non‐target organisms. Regarding the T‐modality, a conclusion on whether the criteria are met or not could not be drawn for non‐target organisms.
POP	Persistence	Metribuzin is not considered to be a persistent organic pollutant (POP) according to point 3.7.1 of Annex II of Regulation (EC) 1107/2009.
	Bioaccumulation
	Long‐range transport
PBT	Persistence	Metribuzin is not considered to be a persistent, bioaccumulative and toxic (PBT) substance according to point 3.7.2 of Annex II of Regulation (EC) 1107/2009.
	Bioaccumulation
	Toxicity
vPvB	Persistence	Metribuzin is not considered to be a very persistent, very bioaccumulative substance according to point 3.7.3 of Annex II of Regulation (EC) 1107/2009.
	Bioaccumulation

^(a)Origin of data to be included where applicable (e.g. EFSA, ECHA RAC, Regulation).